MAP Pharmaceuticals, Inc. (MAPP) Posts Wider than Expected Q1 Loss

MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) reported Q1 EPS of ($0.58), $0.19 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $1 million versus the consensus estimate of $1.1 million.

For earnings history and earnings-related data on MAP Pharmaceuticals, Inc. (MAPP) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Radnostix revenue falls 27% amid product recalls and FDA actions
• Cantor Fitzgerald Reiterates Overweight Rating on Global Net Lease (GNL)